Invention Grant
US07683089B1 4-(Phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
失效
作为特定α2肾上腺素能激动剂的4-（苯基甲基和取代的苯基甲基） - 咪唑-2-硫酮
- Patent Title: 4-(Phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
- Patent Title (中): 作为特定α2肾上腺素能激动剂的4-（苯基甲基和取代的苯基甲基） - 咪唑-2-硫酮
-
Application No.: US11232341Application Date: 2005-09-20
-
Publication No.: US07683089B1Publication Date: 2010-03-23
- Inventor: Todd M. Heidelbaugh , Ken Chow , Phong X. Nguyen , Daniel W. Gil , John E. Donello , Michael E. Garst , Larry A. Wheeler
- Applicant: Todd M. Heidelbaugh , Ken Chow , Phong X. Nguyen , Daniel W. Gil , John E. Donello , Michael E. Garst , Larry A. Wheeler
- Applicant Address: US CA Irvine
- Assignee: Allergan, Inc
- Current Assignee: Allergan, Inc
- Current Assignee Address: US CA Irvine
- Agency: Allergan, Inc.
- Agent John E. Wurst; Kevin J. Forrestal
- Main IPC: A61K31/4164
- IPC: A61K31/4164 ; C07D233/30
Abstract:
Compounds of Formula 1 where the variables have the meaning defined in the specification are agonists of alpha2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors. Additionally some of the claimed compounds have no or only minimal cardivascular and/or sedatory activity. The compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2 adrenergic receptors. Compounds of Formula 1 which have no significant cardiovascular and/or sedatory activity are useful for treating pain and other conditions with minimal side effects.
Information query
